Literature DB >> 27663474

Theory and practice of clinical pharmacodynamics in oncology drug development.

Ralph E Parchment1, James H Doroshow2.   

Abstract

The clinical development of molecularly targeted cancer therapies is enhanced by proof of mechanism of action as well as proof of concept, which relate molecular pharmacodynamics to efficacy via changes in cancer cell biology and physiology resulting from drug action on its intended target. Here, we present an introduction to the field of clinical pharmacodynamics, its medical and laboratory aspects, and its practical incorporation into clinical trials. We also describe key success factors that are useful for judging the quality of clinical pharmacodynamic studies, including biopsy quality and suitability, specimen handling, assay fitness-for-purpose, and reagent quality control. This introduction provides not only context for the following articles in this issue, but also an appreciation of the role of well-conducted clinical pharmacodynamic studies in oncology drug development.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Assay fitness-for-purpose; Biopsy sample quality; Biopsy surrogate tissues; Reagent quality control

Mesh:

Substances:

Year:  2016        PMID: 27663474     DOI: 10.1053/j.seminoncol.2016.07.001

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  6 in total

1.  The use of research biopsies in oncology trials: challenges and controversies.

Authors:  Katherine V Ferry-Galow; Alice P Chen
Journal:  J Hosp Manag Health Policy       Date:  2019-04-01

2.  Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors.

Authors:  Apurva K Srivastava; Melinda G Hollingshead; Jeevan Prasaad Govindharajulu; Joseph M Covey; Dane Liston; Melanie A Simpson; James O Peggins; Donald P Bottaro; John J Wright; Robert J Kinders; James H Doroshow; Ralph E Parchment
Journal:  Mol Cancer Ther       Date:  2018-02-14       Impact factor: 6.261

Review 3.  Effective implementation of novel MET pharmacodynamic assays in translational studies.

Authors:  Apurva K Srivastava; Tony Navas; William G Herrick; Melinda G Hollingshead; Donald P Bottaro; James H Doroshow; Ralph E Parchment
Journal:  Ann Transl Med       Date:  2017-01

4.  The Challenge for Development of Valuable Immuno-oncology Biomarkers.

Authors:  Janice M Mehnert; Arta M Monjazeb; Johanna M T Beerthuijzen; Deborah Collyar; Larry Rubinstein; Lyndsay N Harris
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531

5.  What Can Be Done to Improve Research Biopsy Quality in Oncology Clinical Trials?

Authors:  Katherine V Ferry-Galow; Vivekananda Datta; Hala R Makhlouf; John Wright; Bradford J Wood; Elliot Levy; Etta D Pisano; Alda L Tam; Susanna I Lee; Umar Mahmood; Lawrence V Rubinstein; James H Doroshow; Alice P Chen
Journal:  J Oncol Pract       Date:  2018-10-04       Impact factor: 3.840

6.  T-Cell Heterogeneity in Baseline Tumor Samples: Implications for Early Clinical Trial Design and Analysis.

Authors:  Laura Brennan; Jurriaan Brouwer-Visser; Eveline Nüesch; Maria Karpova; Astrid Heller; Fabien Gaire; Meike Schneider; Bruno Gomes; Konstanty Korski
Journal:  Front Immunol       Date:  2022-04-27       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.